Brain Systems and Cognitive Effects of Parkinson's Disease
This paper examines the brain structures and neurotransmitter systems affected by Parkinson's disease (PD), with particular focus on the substantia nigra, corpus striatum, and basal ganglia, and the role of dopamine and acetylcholine in both motor and cognitive function. Drawing on decades of research from the 1980s through the 2000s, the paper traces how cognitive impairments in PD — including deficits in set-shifting, working memory, visuospatial reasoning, and dementia — illuminate the multifunctional roles of subcortical structures. It also addresses emotional symptoms, the challenges of distinguishing neurologically caused depression from reactive depression, and the implications of pharmacological and surgical interventions for understanding the brain's complex neurotransmitter balance.
- Introduction to Parkinson's Disease: Overview of PD, dopamine, and core motor symptoms
- Primary Symptoms and Early Cognitive Changes: NINDS symptom list and early cognitive research findings
- Dementia in Parkinson's Disease: Chemical vs. Structural Causes: Cholinergic basis of PD dementia versus Alzheimer's plaques
- Frontal Lobe-Like Deficits and the Basal Ganglia: Basal ganglia role in cognition and frontal lobe parallels
- Treatment Approaches and Cognitive Implications: Dopamine therapy, Donepezil, and STN stimulation effects
- Emotional Symptoms and Neural Substrates: Separating reactive depression from neurological emotional change
- Conclusion: Toward an Integrated Understanding: Future research directions and neurotransmission balance
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper integrates a wide range of peer-reviewed sources spanning more than two decades of research, building a coherent chronological narrative of how scientific understanding of PD's cognitive effects evolved.
- It consistently connects empirical findings to broader theoretical implications — for example, using PD-related frontal-lobe-like deficits to argue for functional continuity between the basal ganglia and prefrontal cortex.
- The paper distinguishes carefully between structurally caused and chemically caused impairments, and between neurologically driven emotional symptoms and psychologically reactive ones, adding analytical depth beyond simple description.
Key academic technique demonstrated
The paper demonstrates effective use of extended quotation from primary research sources to anchor and support its analytical claims. Rather than merely summarizing findings, the author quotes key passages and then interprets their significance, linking them to the paper's central argument about the multifunctional role of dopaminergic and cholinergic systems in cognition and emotion.
Structure breakdown
The paper opens with a clinical overview of PD and its neurological basis, then progressively narrows to cognitive and emotional symptoms. It moves chronologically through the research literature — from early 1980s set-shifting studies through 1990s basal ganglia theory to 2000s pharmacological and surgical trials — before concluding with a forward-looking synthesis. This structure mirrors the historical development of the field and effectively shows how each wave of research built on the last.
Introduction to Parkinson's Disease
Parkinson's disease is a crippling, degenerative disorder that primarily affects a movement center of the brain. The disorder creates a shortage or limiting of the action of the neurotransmitter dopamine, which in a healthy brain triggers purposeful movement in the neurons of the affected region. The disease is also shown to affect norepinephrine to some degree. Parkinson's disease is usually progressive, beginning with a single-sided tremor, typically in one hand and particularly when the individual is at rest. It can then progress to tremors in all the limbs, bradykinesia (slow movement), akinesia (an inability to move), rigid limbs, a shuffling gait, and a stooped posture. It is also not uncommon for people with the disease to have reduced facial expressions and to speak in a soft voice as a result of the neurological effects. Individuals may also experience fatigue, depression, personality changes, dementia, and other cognitive function impairments (National Institute of Neurological Disorders and Stroke, 2010).
There is some difficulty in separating the severe functional limitations of the disease and its bleak prognosis from cognitive changes such as clinical depression, as the disorder has limited treatment options and can seriously affect quality of life. It is also clear that knowledge of neurotransmitters and the normal function of receptors and transmitters — both in the healthy brain and in the Parkinson's-affected brain — remains incomplete. Cognitive manifestations, especially dementia, can be positively linked to the disorder itself rather than to a normative cognitive response to decreased quality of life, and are also shown to directly affect the level of disability associated with the disease (Weintraub, Moberg, Duda, Katz & Stern, 2004, pp. 784–788).
Create your account
Always verify citation format against your institution’s current style guide requirements.